Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Non-Current Assets (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Other Non-Current Assets for 13 consecutive years, with $738000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 51.51% to $738000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $738000.0, a 51.51% decrease, with the full-year FY2025 number at $1.2 million, up 7.4% from a year prior.
  • Other Non-Current Assets was $738000.0 for Q4 2025 at Aytu Biopharma, down from $939000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.5 million in Q2 2023 to a low of $457000.0 in Q4 2021.
  • A 5-year average of $968166.7 and a median of $859000.0 in 2022 define the central range for Other Non-Current Assets.
  • Biggest YoY gain for Other Non-Current Assets was 2752.15% in 2021; the steepest drop was 97.1% in 2021.
  • Aytu Biopharma's Other Non-Current Assets stood at $457000.0 in 2021, then soared by 79.65% to $821000.0 in 2022, then increased by 10.48% to $907000.0 in 2023, then skyrocketed by 67.81% to $1.5 million in 2024, then tumbled by 51.51% to $738000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other Non-Current Assets are $738000.0 (Q4 2025), $939000.0 (Q3 2025), and $1.2 million (Q2 2025).